Mimesis at the Forefront of Technological Innovation in Computational Medicine
Catania, October 24, 2024 – Mimesis proudly participated in a significant event organized by the Observatory on Trends and Applications of Supercomputing. This gathering aimed to explore the transformative potential of supercomputing and its implications for the healthcare sector, particularly in computational medicine. Representing Mimesis, Martina Di Salvatore emphasized the critical role that advanced computational resources play in the field of in silico medicine. Mimesis, as a spin-off of the University of Catania, is dedicated to offering innovative solutions for the biomedical and pharmaceutical industries. Through the use of computational models, the company simulates the immune system’s behavior, enabling accurate responses in the context of various health challenges and therapies. Professor Francesco Pappalardo, a key figure in the company and co-leader of Spoke 8 ‘In Silico Medicine and Omics Data’ at the ICSC, highlighted how “in silico medicine is revolutionizing the research and development of new treatments, reducing drug development times and improving the precision of therapeutic interventions.” The event also featured the participation of other promising spin-offs from the University of Catania, as well as notable institutions like Ospedale Cannizzaro, showcasing the vibrant entrepreneurial ecosystem in the region. These organizations are leveraging advanced technologies to contribute to various sectors, highlighting the synergy between academic research and industry innovation. The gathering underscored the growing demand for supercomputing services, with projections indicating a significant increase in need by 2030. This surge presents substantial opportunities for companies that can harness advanced computational tools to drive innovation and enhance healthcare outcomes. As Mimesis continues to push the boundaries of computational medicine, it plays a vital role in shaping the future of healthcare in the region. The company is committed to advancing personalized medicine, aiming to streamline drug development processes and improve the precision of therapeutic interventions, ultimately benefiting patients and healthcare providers alike.
Celebrating Milestones: Mimesis at the In Silico World Final Event, VPH2024
The In Silico World final event at the VPH2024 conference in Stuttgart was a landmark occasion, and the Mimesis group is thrilled to have been a key part of this groundbreaking event. With over 180 participants joining us both in person and virtually, the event provided a valuable platform to celebrate the advancements in #InSilicoMedicine and the collaborative achievements of our community. A standout moment of the conference was Prof. Pappalardo’s presentation, where he addressed the regulatory challenges facing in silico medicine and highlighted the significant progress made in navigating these barriers. His insights were instrumental in framing the current landscape and future directions for regulatory practices in our field. The Mimesis group was honored to showcase our innovative solutions and technological advancements, which represent the forefront of computational modeling and simulation in healthcare. Our work, presented alongside the COmbine group’s contributions, reflects the high level of innovation and dedication that has characterized the In Silico World project. Together, we are pioneering approaches that have the potential to revolutionize patient care through advanced predictive models and virtual simulations. We extend our deepest gratitude to all participants, contributors, and supporters who made this event a success. The collective effort and passion demonstrated by everyone involved have been truly inspiring. As we conclude the In Silico World project, we remain steadfast in our commitment to advancing #InSilicoMedicine and driving innovation in healthcare. At Mimesis, we are excited about the future and eager to continue pushing the boundaries of what’s possible in computational medicine. Our dedication to improving patient outcomes through innovative technologies will guide our efforts moving forward. We look forward to sharing more updates and continuing our journey toward transforming healthcare. Thank you to everyone who has been a part of this incredible endeavor. The future of in silico medicine is bright, and we are excited to continue this journey with our talented partners and the broader scientific community. Stay connected with Mimesis for more news and updates on our latest advancements in #InSilicoMedicine.
Mimesis S.r.l. Celebra il Successo al 🌟 Piaceri Day 2024 🌟
Ieri, 11 luglio 2024, si è tenuto l’evento 🌟 𝐏𝐢𝐚𝐜𝐞𝐫𝐢 𝐃𝐚𝐲 𝟐𝟎𝟐𝟒 🌟, una giornata dedicata alla ricerca promossa dall’Università degli Studi di Catania (UNICT). Questo evento ha rappresentato una straordinaria opportunità per Mimesis S.r.l. e il nostro team di ricerca di condividere il nostro lavoro innovativo e i progressi compiuti nell’ambito delle simulazioni in silico. Un’opportunità unica per Mimesis Partecipare al Piaceri Day 2024 è stato un grande onore per noi. Durante la giornata, abbiamo avuto l’occasione di presentare i nostri progetti più recenti e di discutere le future direzioni del nostro lavoro con colleghi, accademici e altri professionisti del settore. Questo evento ci ha permesso di mettere in mostra le capacità e l’impegno del nostro gruppo di ricerca, nonché di tutto il Dipartimento di Scienze del Farmaco e della Salute dell’Università di Catania. Ringraziamenti e Prospettive Future Vogliamo ringraziare tutti coloro che hanno partecipato al Piaceri Day 2024 e che hanno contribuito a rendere questa giornata un successo. Il supporto e l’interesse dimostrati nei confronti del nostro lavoro sono stati fonte di grande ispirazione per tutto il team di Mimesis. Guardando al futuro, siamo determinati a continuare a innovare e a sviluppare nuove tecnologie in grado di trasformare il panorama della salute e del benessere. Il Piaceri Day 2024 ha rappresentato un importante passo avanti nel nostro percorso e siamo entusiasti di vedere dove ci porteranno le nostre prossime ricerche. Rimanete sintonizzati per ulteriori aggiornamenti e per scoprire le prossime tappe del nostro viaggio!
Do You Know How Long It Takes for a Drug to Reach the Pharmacy?
Webinar: Empowering Ethical and Efficient Drug Development through Advanced Computational
Yesterday, members of Avicenna Alliance were treated to an exclusive webinar that promised to reshape the landscape of drug development. Titled “Empowering Ethical and Efficient Drug Development through Advanced Computational,” the webinar featured Martina Di Salvatore from Mimesis SRL as the keynote speaker. Taking place on Tuesday, May 7th, 2024, at 5:00 pm CET, the webinar delved into the transformative potential of the Universal Immune System Simulator (UISS) in pharmaceutical research. Attendees were given an insider’s look at how UISS is revolutionizing drug development through sophisticated computational models. Among the highlights of the session were insights into the multi-scale, multi-organ, and three-dimensional agent-based simulation of the immune system that UISS offers. Martina Di Salvatore also explored the ethical dimensions of pharmaceutical research with UISS, showcasing its significant reduction in traditional animal testing. Attendees gained valuable insights into the efficiency gains achieved through UISS, including shortened development timelines and lowered research costs. Through real-world examples and case studies, Martina illustrated UISS’s role in streamlining the discovery and optimization of new therapeutic agents. Attendees had the opportunity to delve into the future of drug development, where advanced computational tools like UISS pave the way for more efficient, ethical, and successful outcomes. For those who missed out on this exclusive opportunity, stay tuned for future events hosted by Avicenna Alliance. If you’re interested in becoming a member and gaining access to exclusive webinars like this one, reach out to Avicenna Alliance at manager@avicenna-alliance.com. Stay updated with Avicenna Alliance for more cutting-edge insights and opportunities to shape the future of drug development!
Featured on #UnictMagazine by #Unict: Breakthrough Research on the #JollyVaccine!
We’re excited to share that our research team at the University of Catania is front and center in #UnictMagazine with our latest groundbreaking study on the #JollyVaccine! In this pioneering investigation, we’ve dedicated ourselves to crafting an innovative solution to address the complexities surrounding vaccination, specifically focusing on the concept of a “Jolly Vaccine.” This initiative has garnered attention from both within and outside the scientific community, as it holds the promise of significantly advancing preventive medicine. Our methodology integrates state-of-the-art technologies with a profound understanding of immunological science, with the goal of surpassing the limitations associated with conventional seasonal vaccines. The #JollyVaccine aims to provide broader and longer-lasting protection against a diverse array of pathogens, thereby enabling enhanced adaptability in managing health crises and bolstering resilience against potential future threats. This study underscores the University of Catania’s unwavering commitment to fostering innovation and excellence in scientific inquiry, thereby contributing to global well-being and health security. We extend our gratitude to all who have supported and contributed to this achievement, and we eagerly anticipate sharing further updates on the progress of our research. Here’s the link to the article: https://www.unictmagazine.unict.it/simulare-il-sistema-immunitario-sviluppare-un-vaccino-influenzale-universale?fbclid=IwAR2eVfK8qrGGn1spHqbnE1m4QFHUu3-5VFHLA3lc5OjwnsYL6PaR1UbBEsg&sfnsn=scwspwa
UISS: Revolutionizing In Silico Simulation – A Roundup of Recent Recognition
In the dynamic realm of medical research and technology, breakthroughs often fly under the radar until they gain widespread acclaim. However, for the Universal Immune System Simulator (UISS), created by Professor Francesco Pappalardo and his team, recognition has recently poured in from seven prestigious newspapers. This marks a pivotal moment not only for the UISS but also for the field of immunology simulation. Professor Pappalardo, a respected figure in the scientific community and the founder of Mimesis, has been a driving force behind innovative research for years. Leading the Combine Group, he has tirelessly pursued advancements in immunology through simulation, culminating in the creation of UISS—a groundbreaking platform poised to revolutionize our understanding and study of the immune system. The Recognition: The UISS has caught the attention of seven notable newspapers, each acknowledging its potential to transform medical research: The recognition received by UISS and Professor Pappalardo underscores their groundbreaking contributions to Health sector. Looking ahead, UISS is poised to push the boundaries of medical research, paving the way for transformative discoveries that benefit humanity. The journey towards a deeper understanding of the immune system has just begun, and with UISS leading the charge, the future appears exceptionally promising.
Advancing Medicine: Insights from the Workshop on Regulatory Barriers to In Silico Trials in Catania
Nestled within the historic Monastero dei Benedettini in Catania, the annual Workshop on Regulatory Barriers to In Silico Trials convened on March 14-15, drawing together key figures and enthusiasts from the In Silico community. This gathering provided a unique opportunity to delve into the intricate challenges surrounding the integration of simulation technologies in medical practices. Throughout the workshop, attendees were immersed in a diverse array of discussions centered around navigating regulatory hurdles in the realm of in silico medicine. Esteemed speakers such as Marco Viceconti, Francesco Pappalardo, and Jeff Bischoff shared their invaluable perspectives, enriching the discourse with their expertise and insights. Beyond its academic significance, the workshop fostered an atmosphere of collaboration and knowledge sharing, underscoring the collective strength of the In Silico community. Through vibrant exchanges and shared experiences, participants reaffirmed their commitment to driving innovation and overcoming obstacles within the field. Reflecting on the workshop, it is evident that the In Silico community has rapidly emerged as a pivotal force within the medical landscape. From pioneering research endeavors to transformative applications, the community’s dedication to pushing the boundaries of possibility has reshaped the trajectory of healthcare. As attendees departed from the workshop, they carried with them a renewed sense of purpose and determination. Armed with newfound knowledge and fortified connections, they are poised to continue their journey towards surmounting regulatory barriers and propelling advancements in in silico trials. In summary, the workshop in Catania served as a testament to the collective resolve and ingenuity of the In Silico community. With each gathering, the community reaffirms its commitment to driving positive change and revolutionizing the future of medicine through the transformative power of in silico methodologies.
Double Feature: Highlighted Twice in Unict Magazine!
We are delighted to share with you an exciting update: our endeavors have been spotlighted not once, but twice in the esteemed pages of Unict magazine! Article #1: Delve into an exploration of Mimesis. From its conceptualization to its present iteration, uncover how innovation drives our progress. Article #2: Prepare for a momentous revelation! We have received significant updates from the European Medicines Agency (EMA) that promise to reshape our trajectory. Anticipate a transformative shift in our journey ahead. For a comprehensive insight, we invite you to peruse the complete features via the following link:https://www.unictmagazine.unict.it/ We extend our sincere gratitude to Unict magazine for the esteemed recognition, and we commend our dedicated team for their unwavering commitment. #DoubleFeature #UnictMagazine #Innovation #EMA #TeamEffort 🌟